We are live on ! Find out more
DM

Deerfield Management Portfolio holdings

AUM $8.48B
1-Year Est. Return 99.04%
This Fund
S&P 500
This Quarter Est. Return
+29.85%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$3.09B
AUM Growth
+$304M
Cap. Flow
-$377M
Cap. Flow %
-12.21%
Top 10 Hldgs %
47.14%
Holding
153
New
43
Increased
25
Reduced
27
Closed
29

Top Buys

Rank Stock Value
1
ASPX
AUSPEX PHARMACEUTICALS INC COM STK (DE)
ASPX
+$99.9M
2
ABBV icon
AbbVie
ABBV
+$92.7M
3
LRMR icon
Larimar Therapeutics
LRMR
+$41.5M
4
WBA
Walgreens Boots Alliance
WBA
+$40.8M
5
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
+$36.4M

Top Sells

Rank Stock Value
1
AUXL
AUXILIUM PHARAMCEUTICALS INC
AUXL
+$216M
2
AGN
Allergan Inc
AGN
+$129M
3
RNA
PROSENSA HLDGS N V ORD SHS (NLD)
RNA
+$62.2M
4
NVRO
NEVRO CORP.
NVRO
+$40.5M
5
AERI
Aerie Pharmaceuticals
AERI
+$36.3M

Sector Composition

Rank Sector Weight
1 Healthcare 60.38%
2 Financials 2.52%
3 Technology 0.47%
4 Industrials 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ABT icon
101
Abbott
ABT
$175B
$602K 0.02%
+13,000
New +$597K
VTRS icon
102
Viatris
VTRS
$20.1B
$594K 0.02%
+10,000
New +$570K
NKTR icon
103
Nektar Therapeutics
NKTR
$2.31B
$502K 0.02%
+3,040
New +$625K
CSCI
104
DELISTED
COSCIENS Biopharma Inc. Common Stock
CSCI
$482K 0.02%
+90
New +$516K
MZOR
105
DELISTED
Mazor Robotics Ltd.
MZOR
$470K 0.02%
+41,861
New +$478K
HMSY
106
DELISTED
HMS Holdings Corp.
HMSY
$462K 0.02%
+29,900
New +$562K
RAD
107
DELISTED
Rite Aid Corporation
RAD
$459K 0.01%
+2,638
New +$411K
CELG
108
DELISTED
Celgene Corp
CELG
$403K 0.01%
+3,500
New +$418K
CASC
109
DELISTED
Cascadian Therapeutics, Inc.
CASC
$233K 0.01%
23,867
-42,550
-64% -$417K
ESPR
110
DELISTED
Esperion Therapeutics
ESPR
$232K 0.01%
+2,500
New +$161K
IMRS
111
DELISTED
IMRIS INC COMMON SHARES (CANADA)
IMRS
$141K ﹤0.01%
147,076
– –
ARAY icon
112
Accuray
ARAY
$30.8M
– –
-1,870,943
Closed -$14.1M
EW icon
113
Edwards Lifesciences
EW
$49.4B
– –
-60,000
Closed -$1.27M
EXEL icon
114
CALL
Exelixis
EXEL
$14.1B
– –
-1,000,000
Closed -$1.44M
HUM icon
115
CALL
Humana
HUM
$48B
– –
-280,000
Closed -$40.2M
RMD icon
116
ResMed
RMD
$28.9B
– –
-296,300
Closed -$16.6M
SVRA icon
117
Savara
SVRA
$1.13B
– –
-10,000
Closed -$392K
ZTS icon
118
Zoetis
ZTS
$32.1B
– –
-25,097
Closed -$1.08M
NVRO
119
DELISTED
NEVRO CORP.
NVRO
– –
-1,047,093
Closed -$40.5M
EGRX
120
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
– –
-284,653
Closed -$4.41M
ICPT
121
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
– –
-60,393
Closed -$9.42M
FLXN
122
DELISTED
Flexion Therapeutics, Inc.
FLXN
– –
-99,847
Closed -$2.02M
PFNX
123
DELISTED
Pfenex Inc.
PFNX
– –
-625,640
Closed -$4.49M
KND
124
DELISTED
Kindred Healthcare
KND
– –
-37,611
Closed -$684K
ANTH
125
DELISTED
Anthera Pharmaceuticals, Inc.
ANTH
– –
-211,482
Closed -$2.67M
2 3 4
5
6

Similar funds

FT
Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return
GRQ
Gardner Russo & Quinn Lancaster, Pennsylvania $8.5B AUM 9.79% 1-Year Est. Return
AV
ASR Vermogensbeheer Utrecht, Netherlands $8.5B AUM 25.14% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
VA
Valmark Advisers Akron, Ohio $8.42B AUM 14.36% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $8.4B AUM 63.34% 1-Year Est. Return
IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
NW
NewEdge Wealth Pittsburgh, Pennsylvania $8.39B AUM 24.47% 1-Year Est. Return

Deerfield Management's Q1 2015 Portfolio in Review

As of Q1 2015, Deerfield Management held 153 positions worth $3.09B, up 11% from $2.78B the previous quarter. Its ten largest holdings account for 47% of the portfolio.

Deerfield Management withdrew a net $377M in Q1 2015, closing 29 positions and reducing 27 holdings. Its most notable exit was AUXILIUM PHARAMCEUTICALS INC, an estimated $216M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 60% of assets, up from 52% a quarter earlier, followed by Financials and Technology.

Against the trend, Deerfield Management opened a new position in AbbVie worth $89.8M.

  • Deerfield Management's largest Q1 2015 buy was AbbVie: 1,534,000 shares worth $89.8M.
  • Deerfield Management added most to AUSPEX PHARMACEUTICALS INC COM STK (DE) in Q1 2015, an estimated $99.9M increase.
  • Deerfield Management's biggest Q1 2015 reduction was Aerie Pharmaceuticals, cutting an estimated $36.3M.
  • Deerfield Management fully exited AUXILIUM PHARAMCEUTICALS INC in Q1 2015, selling an estimated $216M.
  • Deerfield Management's ten largest holdings make up 47% of its $3.09B portfolio in Q1 2015.
  • Deerfield Management opened 43 new positions and closed 29 in Q1 2015.
  • Deerfield Management's portfolio value rose 11% quarter-over-quarter to $3.09B.

Based on Deerfield Management's 13F filing for Q1 2015, filed 15 May 2015.